116 / 1498
stratified HR=0.50 95%
CI 0.39; 0.64
p
<.0001
Time (months)
Rituximab maintenance
N=505
Observation
N=513
6
0
12
18
24
30
36
Progression-free rate
0.8
0.6
0.4
0.2
0
1.0
82%
66%
Patients at risk
505
513
472
443
336
230
103
18
469
411
289
195
82
15
PRIMA: Progression-free survival
Salles G, et al. Lancet 2011; 377:42–51
Rituximab maintenance significantly reduced the risk of progression by 50%